Since the beginning of the HIV epidemic, scientists, doctors, and public health experts have spent decades trying to understand the virus and control its spread. Modern treatments now allow people living with HIV to reduce the virus in their bodies to undetectable levels, helping them stay healthy while also preventing transmission to others. Still, these treatments do not eliminate the virus entirely. Now, new research exploring the use of CRISPR gene-editing technology has shown promising results. This raises a question that has lingered for years: are we any closer to a cure for HIV?

What Is CRISPR?

CRISPR, short for Clustered Regularly Interspaced Short Palindromic Repeats, is a powerful gene-editing tool adapted from a natural defense system found in bacteria. It works by acting like precise molecular scissors that can cut, remove, or alter specific sections of DNA inside living cells. Scientists use a guide RNA to direct an enzyme, such as Cas9, to a targeted stretch of genetic material, allowing them to make exact changes.

According to the National Human Genome Research Institute, CRISPR has transformed genetic research because it is faster, more accurate, and more affordable than older gene-editing methods, with applications across medicine, science, and agriculture.

CRISPR Slices HIV Out Of Infected Cells Completely

Researchers at Amsterdam UMC have used Nobel Prize-winning CRISPR gene-editing tools to remove HIV DNA from infected T cells. Their work focused on targeting the virus where it hides inside immune cells known as reservoirs. By attacking parts of the HIV genome that remain stable across different strains, the researchers were able to target the virus in several types of cells, as per BBC.

In laboratory studies, the team successfully eliminated HIV from T cells that typically allow the virus to resurface once antiretroviral treatment is stopped. Unlike current HIV medications, which keep the virus under control but do not remove it, CRISPR physically cuts the viral DNA out of dormant reservoir cells. These hidden cells have been one of the biggest obstacles to finding a cure for HIV for decades.

How CRISPR Works Against HIV

According to the National Institutes of Health, CRISPR can fight HIV in several ways.

Removing the virus: CRISPR can cut out HIV DNA that has integrated into a person’s own genetic material, effectively removing the virus from the cell. This approach has been demonstrated in studies highlighted by the NIH, the World Economic Forum, and other research bodies.

Blocking viral activity: The technology can also disrupt viral genes or target host cell receptors, such as CCR5, which HIV needs to enter cells. This helps prevent new infections from taking hold.

Multiple-target strategies: Scientists are developing approaches that use more than one guide RNA to attack different parts of the virus at the same time. This reduces the chances of HIV mutating and escaping treatment, according to reports from the NIH, Aidsmap, and the World Economic Forum.

Study Details And Key Findings

Led by Dr Elena Herrera-Carrillo, the research team tested a CRISPR-Cas system using two guide RNAs aimed at conserved regions of the HIV genome. By focusing on these shared genetic sequences, the scientists hoped to create a treatment effective against many HIV variants. One major challenge they identified was the size of the delivery system used to transport the CRISPR components into cells. The vector carrying the gene-editing tools was initially too large.

To address this, the team tested different methods to shrink the CRISPR cassette and improve delivery. They compared several CRISPR-Cas systems derived from different bacteria in HIV-infected CD4+ T cells. Among them, saCas9 showed especially strong results. With one guide RNA, it completely shut down HIV activity, and with two guide RNAs, it fully removed viral DNA from the cells.

Reducing the vector size improved delivery efficiency, and the researchers were also able to target hidden HIV reservoir cells by focusing on proteins found on the surface of CD4+ and CD32a+ cells.

The researchers stated: “We have developed an effective combined CRISPR approach that attacks HIV in different cell types and in the locations where it hides. We also showed that these treatments can be delivered specifically to the cells that matter. This work marks an important step toward designing a cure strategy.”

What Happens Next?

Looking ahead, the authors explained that their next goal is to improve how the treatment is delivered so it reaches most HIV reservoir cells in the body. They plan to combine CRISPR-based therapies with receptor-targeting tools and move into preclinical testing to closely examine safety and effectiveness.

They added: “This will help ensure that CRISPR-Cas is delivered mainly to reservoir cells while avoiding healthy cells. Our aim is to make the system as safe as possible for future use in patients. Finding the right balance between effectiveness and safety is essential. Only then can clinical trials begin to explore whether this cure strategy can disable HIV reservoirs in humans.”

Japan has been granted the world's-first approval for two stem cell–based regenerative therapies, one for Parkinson’s disease and one for severe heart failure.

Stem cells are unspecialized foundational cells with the unique ability to self-renew and differentiate into various specialized cell types, such as muscle, blood or brain cells. They are essential for tissue repair, regeneration, and development, acting as an internal repair system.

Stem cell therapy, or regenerative medicine, uses stem cells or their derivatives to repair, replace, or regenerate diseased, dysfunctional, or injured tissue. It involves guiding stem cells to become specialized cells (heart muscle, nerve, or blood cells) to treat conditions like blood cancers, orthopaedic injuries, and neurodegenerative diseases.

Based on the Japanese approval, the Parkinson’s stem cell therapy treatment uses induced pluripotent stem cells (iPSCs) that are converted into dopamine-producing neurons and transplanted into the brain to replace cells lost during the disease.

Moreover, the heart failure therapy involves placing sheets of stem cell–derived heart muscle cells onto the heart, which may help restore cardiac function by promoting tissue repair and new blood vessel growth.

Both therapies received conditional approval, meaning they can be used clinically while researchers continue to collect additional safety and effectiveness data from patients.

What Is Parkinson's Disease?

Parkinson's disease is a progressive, neurodegenerative movement disorder caused by the loss of dopamine-producing brain cells, primarily affecting people over 60. Apart from motor loss, the disease also causes cognitive decline, depression, anxiety and swallowing problems.

The first symptom may be a barely noticeable tremor in just one hand or sometimes a foot or the jaw. Over time, swinging your arms may become difficult and your speech may become soft or slurred. The disorder also causes stiffness, slowing of movement and trouble with balance that raises the risk of falls.

Lifestyle Changes Can Prevent Parkinson's Disease

While Parkinson’s disease cannot be entirely prevented, experts suggest several lifestyle modifications that may reduce the risk. Dr Himanshu Champaneri, Senior Consultant in the Department of Neurosciences and Neurosurgery at Marengo Asia Hospitals in Gurugram told India Today that physical activity could aid in maintaining brain health. He recommends engaging in at least 150 minutes of moderate-to-intense exercise per week, including walking, running, swimming, and dancing.

Meanwhile, other experts have suggested that certain types of Parkinson's disease such as vascular Parkinsonism, are linked to the hardening of brain blood vessels. To mitigate this risk, she advises regular exercise, a low-fat diet, and monitoring blood pressure, sugar, and cholesterol levels. Additionally, industrial pollution is associated with an increased incidence of Parkinson's.

She suggests spending time in natural environments away from industrial pollutants to help lower the risk.

Menstruation is not a disability, and therefore, there is no need for mandatory period leaves, said experts, a day after the Supreme Court of India quashed the petition seeking a menstrual leave policy.

The top court expressed concerns that a law making paid leave during menstrual pain compulsory could harm the careers of young women and deprive them of equal opportunities.

While such a policy may look appealing from a “rights perspective,” the court noted it could have “long-term impacts.”

According to the 2025 Periodic Labor Force Survey (PLFS) data released by the Ministry of Statistics and Program Implementation (MoSPI), women’s labor force participation (LFPR) showed significant growth, reaching 35.3 percent in December 2025, driven largely by a consistent rise in rural areas, which peaked at 40.1 percent.

The female worker population ratio (WPR) also increased, reaching a yearly high in December, highlighting greater engagement in the workforce.

However, India’s female participation remains notably lower than the global average of nearly 49 percent and the OECD average of 67 percent, indicating a persistent, though shrinking, gender gap.

In this context, the court observed that a mandatory period leave policy could create the impression that women “still have some natural issues” and “are not at par with male persons.”

“Will an employer be happy if an employee takes leave every month? You risk creating a situation where employers may be reluctant to hire women,” the bench said.

Period Pain is Real. Paid Leave Unnecessary

HealthandMe spoke to several experts who agreed with the Supreme Court’s view, noting that while period pain and related concerns are real, they do not warrant paid leave for all women employees.

Periods affect women worldwide. For some, it comes with severe back pain, headaches, cramps, fatigue, and other symptoms. For others, the days pass with little discomfort.

“I feel mandatory menstrual leave for all female employees is unnecessary. While menstrual issues are real, not everyone suffers from them. Young women experience debilitating pain in about 1 in 10 cases, while women in their 40s may experience heavier bleeding, perhaps debilitating in 1 out of 7 individuals,” Dr. Ruma Satwik, Senior Consultant at Sir Ganga Ram Hospital, New Delhi, told HealthandMe.

Dr. Sabine Kapasi, a public health expert and UN advisor, emphasized that menstrual health deserves significant policy attention.

“But a universal requirement for leave may not be sufficient and is not necessarily the best approach,” she added.

Women have long faced societal and workplace stereotypes, with gender bias evident in wages, hierarchies, and opportunities. A LinkedIn report shows that gender disparity is more pronounced in leadership roles: in 2025, women held only 18 percent of top positions in India, far lower than their overall workforce representation.

“A policy must avoid inadvertently perpetuating gender bias in employment or career advancement,” Kapasi told HealthandMe.

During the Supreme Court hearing, Chief Justice Surya Kant said that with the mandatory menstrual leave law, employers might hesitate to hire women.

“We are creating ‘All Women Teams’ and ‘All Women Service Centers.’ How will they function if such a leave policy is approved? Menstruation is not a disability. It is a biological fact that women have managed over generations,” Indira Murthy, Retired Joint Secretary, Government of India, Advocate, High Court and Supreme Court, and Arbitrator, told HealthandMe.

A Sustained and Flexible Approach

Experts acknowledged the genuine challenges women face during menstruation and suggested alternative measures, including work-from-home arrangements.

Murthy noted that the Supreme Court emphasized voluntary employer initiatives, while also stating that proper institutional arrangements should ensure hygiene and safety for women and children.

“For some women, periods are very uncomfortable. They may be unable to work during these days. Companies can provide flexibility and allow period leaves,” said Dr. Alpna Kansal, President of IMA Ghaziabad.

Kapasi recommended a more sustained approach in workplaces, urging employers to recognize that conditions like endometriosis or severe dysmenorrhea can significantly impact well-being and productivity.

Flexible, stigma-free policies can help women while maintaining workplace fairness.

“Menstrual health awareness, workplace flexibility, access to care, and supportive leave policies integrated into broader occupational health frameworks should be priorities. Women’s health can be safeguarded with a balanced strategy without causing structural disadvantages at work,” Kapasi added.

Dr. Satwik noted that most cases of pain or heavy bleeding can be managed with medication.

“Only in rare cases would symptoms be refractory to treatment, requiring injections or surgical intervention. Those experiencing debilitating symptoms should be granted leave as part of standard sick leave,” she said.

Murthy emphasized that the Supreme Court did not propose a blanket ban.

“No one-size-fits-all policy works. Policy-making should benefit even the last person in the queue. Work-from-home arrangements are a sustainable solution to this issue,” she said.

The American Heart Association (AHA), along with the American College of Cardiology (ACC), today released new guidelines for managing dyslipidemia.

Dyslipidemia can be defined as abnormal levels of one or more types of lipids or lipoproteins in the blood, including cholesterol and triglycerides.

The new guidelines, jointly published in JACC, the flagship journal of ACC, and Circulation, the flagship journal of the AHA, emphasize the need to reduce cardiovascular risk by starting to screen early. It also calls for making lifestyle changes with a proper diet, weight control with exercise, to curb the risk of atherosclerotic cardiovascular disease (ASCVD).

ASCVD is caused by the buildup of fatty deposits in the arteries and is the leading cause of death globally.

The guidelines replace the 2018 Guideline on the Management of Blood Cholesterol and offer a comprehensive “one-stop shop”.

Instead of the usual focus on just bad cholesterol, it addresses the need to evaluate, manage, and monitor all dyslipidemias, including high blood cholesterol, hypertriglyceridemia, and elevated lipoprotein(a) (Lp[a]).

“While we want to try to optimize healthy lifestyle habits as the first step to lower cholesterol, we realize that if lipid numbers aren’t within the desirable range after a period of lifestyle optimization, we should consider adding lipid-lowering medication earlier than we would have considered 10 years ago,” said Roger S. Blumenthal, chair of the guideline writing committee.

“Lower [LDL-C] for longer, just like lower blood pressure for longer, results in much greater protection against future heart attack and stroke risk,” he added.

What Does The Guideline Say:

1. Early Screening

Early intervention through early screening and healthy lifestyle changes, starting from childhood, is the primary focus of the guidelines. It recommends:

• Children (9-11 years): Cholesterol screening if never done before.
• Adults (30-79 years): Evaluate 10- and 30-year ASCVD risk to determine the need for early intervention
• Considering lipid-lowering therapy for young adults with -- persistent LDL of at least 160 mg/dL, strong family history of ASCVD and/or at least 10 percent 30-year risk for ASCVD

• Family history of heart disease
• Chronic inflammatory diseases (e.g., lupus, rheumatoid arthritis)
• Metabolic conditions like obesity, diabetes, or chronic kidney disease
• Higher-risk ancestries, including South Asian or Filipino
• Early menopause, preeclampsia, gestational diabetes

• A healthy weight,
• regular physical activity,
• avoiding tobacco,
• healthy sleep habits
• cholesterol-lowering medications

2. LDL-C cholesterol

The guidelines state that individuals with healthy LDL-cholesterol levels or high-density lipoprotein-cholesterol (HDL-C), “cannot ‘get out of jail free’ card”. It is important to measure other biomarkers, such as:

• lipoprotein(a) [Lp(a)],
• apolipoprotein B (apoB),
• high-sensitivity C-reactive protein (hsCRP)
• elevated triglycerides

Further, it indicates that LDL-C should be less than

• 100 mg/dL borderline or intermediate risk
• 70 mg/dL for people at high risk
• 55 mg/dL for people at very high risk/need secondary prevention

The guidelines recommend:

• Starting lipid-lowering therapy for people age 40 or older with chronic kidney disease (stage 3 or higher), HIV or Type 1 or Type 2 diabetes
• Continuing lipid-lowering therapy in people being treated for cancer, unless contraindicated
• Deferring most lipid-lowering therapies during conception, pregnancy and lactation